Meningococcal Vaccine Development for Africa
Author Information
Author(s): Rolando Pajon, Andrew M. Fergus, Oliver Koeberling, Dominique A. Caugant, Dan M. Granoff
Primary Institution: Children's Hospital Oakland Research Institute
Hypothesis
The NOMV vaccine would elicit broader serum bactericidal antibody responses against the strains from Africa than the recombinant fHbp vaccines.
Conclusion
NOMV vaccines from mutants with increased fHbp expression elicit an antibody repertoire with greater bactericidal activity than recombinant fHbp vaccines.
Supporting Evidence
- Eighty-six of the isolates (81%) had one of four prevalent fHbp sequence variants.
- More than one-third of serogroup A isolates and two-thirds of W-135 isolates tested had low fHbp expression.
- NOMV vaccines elicited broad anti-fHbp bactericidal activity.
Takeaway
Researchers studied bacteria that cause meningitis in Africa to see if a new type of vaccine could work better than older ones. They found that the new vaccine was more effective.
Methodology
The study investigated genes encoding fHbp in 106 serogroup A, W-135, and X case isolates from 17 African countries and assessed the bactericidal activity of antisera from mice immunized with different vaccines.
Potential Biases
Potential bias due to the limited geographic representation of isolates and the use of mouse models for immunogenicity testing.
Limitations
The study only included 106 case isolates from 17 countries, with a significant portion from Burkina Faso, and the adjuvant used in mice is unsuitable for humans.
Participant Demographics
Isolates were from patients in 17 African countries, primarily from the meningitis belt.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website